LakeShore Biopharma Co EBIT

LakeShore Biopharma Co's ebit stands at $-200M as of March 2024. That compares with $-9.4M in the prior-year period — down 2021.5% year over year. That is below the sector sector average of $-6.4M. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

LakeShore Biopharma Co reported $-200M in EBIT versus $-9.4M a year earlier — a 2021.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

LakeShore Biopharma Co sits lower the its sector benchmark ($-6.4M) with a EBIT of $-200M. That is roughly 3018.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-9.4M in the prior-year period — down 2021.5% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how LakeShore Biopharma Co's EBIT evolved across reporting periods, while the comparison chart places LSB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.